Your session is about to expire
← Back to Search
Seclidemstat + Chemotherapy for Ewing Sarcoma
Study Summary
This trial is testing a new cancer drug in patients with sarcoma, specifically those with myxoid liposarcoma or other sarcomas with similar chromosomal translocations to Ewing sarcoma. The trial will also test a combination of seclidemstat with topotecan and cyclophosphamide in patients with Ewing sarcoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had targeted radiation therapy recently.I haven't had any cancer treatments in the last 3 weeks.My blood tests show normal organ function and I haven't needed a blood transfusion in the last week.My brain cancer is getting worse or causing symptoms.I still have side effects from previous treatments that are not mild.I have been treated with LSD1 inhibitors for cancer.I haven't taken any oral tyrosine kinase inhibitors in the last 14 days.I haven't taken long-acting bone marrow stimulants in the last 14 days or short-acting ones in the last 7 days.I agree to use contraception while on this trial.I am mostly active and can care for myself regardless of my age.I have not had major surgery in the last 3 weeks.I am HIV-positive and on combination antiretroviral therapy.I am at least 12 years old and weigh 40 kg or more.I have a history of cancer.I am taking medications that cannot be stopped before starting the trial.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I haven't had cancer in the last 5 years, except for skin cancer.I have had a bone marrow or stem cell transplant within the last 84 days.I am willing to provide tumor biopsies, unless it's not safe for me or I'm under 18.I haven't had immunotherapy in the last 28 days.I am not currently on any cancer treatment or experimental drugs.I have had a condition where my lymphocytes grow abnormally.I do not have uncontrolled heart disease or abnormal heart rhythms.
- Group 1: Myxoid Liposarcoma
- Group 2: Sarcomas with FET-family translocations, including demoplastic small round cell tumors
- Group 3: Ewing sarcoma, combination therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what indications is Seclidemstat ordinarily prescribed?
"Seclidemstat has been approved to effectively treat multiple sclerosis and is also being explored for its potential efficacy against leukemia, myelocytic acute sarcoma, and retinoblastoma."
What is the current number of medical facilities that are conducting this experiment?
"Fox Chase Cancer Center in Philadelphia, Sarcoma Oncology Research Center in Santa Monica and H. Lee Moffitt Cancer Center and Research Institute in Tampa are a few of the 16 sites that are currently enrolling patients for this study."
Are there any additional research projects which have utilized Seclidemstat?
"Seclidemstat was initially investigated in 1997 by the City of Hope Comprehensive Cancer Center, with 1213 studies having been completed since then. 853 are actively recruiting participants at this moment, with many being conducted in Philadelphia, Pennsylvania."
Are there still opportunities to participate in this experiment?
"According to the details found on clinicaltrials.gov, this research is actively recruiting patients. First posted in June 2018 and last edited in August 2022, it is currently open for enrollment."
How many individuals are currently participating in this trial?
"Affirmative. The clinical trial's information hosted on clinicaltrials.gov reveals that the study, which was initially posted on June 4th 2018, is still in search of volunteers. Up to 50 participants are necessary from 16 distinct medical sites."
Has Seclidemstat received regulatory approval by the FDA?
"Seclidemstat has not undergone extensive clinical trials, so its safety is rated as a 1. This reflects the fact that Phase 1 of this medication's testing only provides minor evidence on efficacy and security."
Share this study with friends
Copy Link
Messenger